Journal Article Summary
The article investigates the potential role of the levonorgestrel-releasing intrauterine system (LNG-IUS) in reducing the risk of ovarian cancer. Ovarian carcinoma is a significant health concern due to its high prevalence and low survival rates, making it crucial to explore preventive measures. The authors aimed to systematically review existing literature and analyze whether the use of LNG-IUS could offer any protective benefits against developing ovarian cancer.
To conduct this study, the authors systematically reviewed literature up to December 2020, identifying relevant studies that assessed the impact of LNG-IUS on ovarian cancer risk. They ultimately included three studies in their meta-analysis, which collectively analyzed data from over 20 million person-years. The findings indicated that LNG-IUS use did not significantly lower the risk of ovarian cancer compared to non-users, with an odds ratio suggesting no protective effect. However, the limited number of studies included means that definitive conclusions cannot be drawn at this time.
The article acknowledges several limitations, including the small number of studies and the lack of adjustment for various confounding factors, such as the use of other hormonal contraceptives. Patients should be aware that while LNG-IUS is widely used for contraception and other gynecological conditions, its role in ovarian cancer prevention remains uncertain. It is advisable for readers to discuss their individual risks and contraceptive options with a healthcare professional to make informed decisions regarding their reproductive health.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- D’Alessandro Gloria, Frigerio Matteo, Barra Fabio, Costantini Sergio, Gustavino Claudio, Ferrero Simone. Systematic review and meta‐analysis on the impact of the levonorgestrel‐releasing intrauterine system in reducing risk of ovarian cancer. International Journal of Gynaecology and Obstetrics 2021. DOI: 10.1002/ijgo.13737. PMID: 33969485. PMCID: PMC9290617.
Featured Pill Pals Product
My Way (Levonorgestrel) 1.5 mg Tablet - Generic For Plan B and Morning After Pill --- Lupin Pharma --- Over The Counter
My Way (Levonorgestrel) 1.5 mg Tablet – Generic For Plan B and Morning After Pill — Lupin Pharma — Over The Counter is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. This is an Over The Counter Product, so no prescription is required.However, your prescriber can still write for it as a prescription, if desired.
